Skip to main content
. 2017 Mar 28;4(1):57–69. doi: 10.1007/s40744-017-0060-8

Fig. 2.

Fig. 2

Clinical efficacy outcomes for CZP ITT patients (N = 235), and the CZP monotherapy (n = 110) and CZP+MTX (n = 125) sub-populations: a ACR20/50/70 (NRI/LOCF); b mean SDAI (absolute values, LOCF); c Mean CDAI (absolute values, LOCF); d mean tender joint count (TJC; absolute values, LOCF) and swollen joint count (SJC; absolute values, LOCF)